[Clinical studies of cefminox in the pediatric field].
The in vitro antibacterial activity of cefminox (CMNX, MT-141) was nearly equal to that of CTX, LMOX, CMZ and CPZ against the 4 species of clinically isolated strains. CMNX was applied to a total of 17 patients including 11 cases of bronchitis, 4 cases of pneumonia and 2 cases of urinary tract infection. The results showed an efficacy rate of 94% (16/17). In the 4 patients from whom the isolation of pathogenic organisms was possible, the bacteriological response to CMNX was appreciable the efficacy rate being 80% (4/5). No side effect of the drug was observed.
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy*; D002513:Cephamycins / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004352:Drug Resistance, Microbial; D005260:Female; D006190:Haemophilus / Q000187:drug effects; D006801:Humans; D007223:Infant; D008297:Male; D011014:Pneumonia / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D002513:Cephamycins; C046079:cefminox